ClinicalTrials.gg
RecruitingNCT06577779Updated Apr 29, 2026

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

A Phase 4 interventional study of Methylphenidate Hydrochloride Extended Release Capsule in Attention-deficit/Hyperactivity Disorder, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by NYU Langone Health · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity — 19 open to participants now, 21 under way, 1 of them phase 3. Methylphenidate · Attention Deficit Disorder with Hyperactivity.

Planned enrollment
133rd of 179
30 · median 68
Started
2025
with 1 other
Phase 4
87 of 181
13 open now
Primary completion
2026-06
later than 7 of 20 live
Registered
175th of 181
by date

Among the 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity, this one is the 133rd largest by planned enrollment of the 179 interventional ones that give a count, is one of 2 that started in 2025, is one of 87 in phase 4, reaches primary completion later than 7 of the 20 other live ones, and was the 175th registered.

Attention Deficit Disorder with Hyperactivity

1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

19 of the 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity are open now, in 7 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About methylphenidate

Methylphenidate: first FDA approval 1955 (RITALIN), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

The goal of this study is to extend the efficacy evidence of sustained release methylphenidate compound (JornayPM) in adults with Attention-deficit/hyperactivity disorder (ADHD). JornayPM has recently been approved for treatment of patients 6 years and older with ADHD; the release mechanism is unique among ADHD products in that it is taken in the evening, with effects in the morning upon awakening and then throughout the subsequent day. Of note, to date, there is no clinical data as to the tolerability or clinical effects or dosing in adults with ADHD; therefore the primary aim of this trial is to gather the first set of these data.

03

Conditions studied

  • Attention-deficit/Hyperactivity Disorder

Keywords

  • ADHD
  • Adult ADHD
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults ages 18-60 years, inclusive at the time of consent
  2. Able to provide signed
  3. Any gender
  4. Subjects with a current primary (DSM) -5 diagnosis of ADHD of predominantly inattentive presentation, or combined presentations) as confirmed by the Adult ADHD Clinical Diagnostic Scale (ACDS) Version 1.2.
  5. Subjects who are not receiving any pharmacological treatment for ADHD must have an DSM AISRS 18 item total score of ≥ 28 at screening. Subjects who were previously receiving pharmacological treatment for ADHD at screening must have a minimum total DSM AISRS 18 item score of ≥ 22 at screening
  6. Dysthymia and anxiety disorders in remission, but stable on psychiatric medication for three weeks or more at the discretion of principal investigator will be allowed. Medication for these disorders to remain constant for the duration of the protocol.
  7. Subjects, who have not used stimulant medication in the past 2 months.
  8. Occasional use of marijuana (less than 3 times weekly) will be allowed during screening process until subject is enrolled into the study. After subject is enrolled onto Jornay PM, subject is asked to complete an attestation. The attestation will state that the subject will not consume marijuana while in the study.
  9. No illicit substance will be allowed at screening or during the study.

Exclusion criteria

Exclusion Criteria:

  1. Known to methylphenidate, or product components.
  2. Concurrent treatment with a monoamine oxidase inhibitor (MAOI), or use of an MAOI within the preceding 14 days.
  3. Lifetime bipolar disorder, psychotic disorders, autism, intellectual disability except mood disorders accepted under the inclusion criteria at the discretion of the principal investigator.
  4. Active suicidality within past year, or history of suicide attempt in past 2 years
  5. Any history of severe past drug dependence determined by the Mini International Neuropsychiatric Interview (MINI) (i.e., a focus of clinical attention or a cause of substantial social or occupational difficulty)
  6. Concurrent substance abuse and/or history of substance use within 6 months (except for marijuana use of less than three times a week and/or history of excessive marijuana use of less than three times a week within 6 months).
  7. Use of any prescribed benzodiazepine
  8. Any unstable medical or neurological condition; medical abnormalities such as cardiovascular abnormalities, and any chronic condition of the central nervous system
  9. Antidepressants and anti-anxiety agents (including benzodiazepines) taken in stable doses will be allowed, while other psychotropic medications, including hallucinogens, mood stabilizers, antipsychotics will not be allowed
  10. Known nonresponse to MPH treatment
  11. History of allergic reaction or sensitivity to MPH
  12. Female of childbearing age, who are breastfeeding, pregnant, planning to be pregnant or men planning to make a woman pregnant during the study or for one-month post study
  13. PI/clinician discretion
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Seven weeks of Jornay PM treatment

    Enrolled participants will begin with a two-week observation stabilization before starting treatment with Jornay PM. Participants found to have ≥30% change in their total Adult ADHD Investigator Symptom Rating Scale (AISRS) scores during the two-week observation stabilization period treatment will be discontinued from the study. Remaining participants will initiate a 7 week open-label treatment with Jornay PM.

    Drug: Methylphenidate Hydrochloride Extended Release Capsule

  • Experimental
    Five weeks of Jornay PM treatment

    Enrolled participants will begin with a two-week observation stabilization before starting treatment with Jornay PM. Participants found to have ≥30% change in their total Adult ADHD Investigator Symptom Rating Scale (AISRS) scores during the two-week observation stabilization period treatment will be discontinued from the study. Remaining participants will initiate a 5 week open-label treatment with Jornay PM followed by a two week observation period; not receiving Jornay PM.

    Drug: Methylphenidate Hydrochloride Extended Release Capsule

Interventions

  • DrugMethylphenidateStudies of MethylphenidateMethylphenidate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will start at dose of 40mg (DR/ER-MPH) day with titrations of 20mg leading to a maximum dose of 100mg (DR/ER-MPH).

    Also known as: Jornay PM

06

What researchers measure

Primary outcomes

  1. Change in Expanded Adult ADHD Investigator Symptom Rating Scale (AISRS) Score from Baseline to Week 3

    The expanded AISRS is an 18-item questionnaire assessing symptoms of adult ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate more severe symptoms of ADHD.

    Time frame: Baseline, Week 3

  2. Change in Expanded Adult ADHD Investigator Symptom Rating Scale (AISRS) Score from Baseline to Week 10

    The expanded AISRS is an 18-item questionnaire assessing symptoms of adult ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate more severe symptoms of ADHD.

    Time frame: Baseline, Week 10

Secondary outcomes

  1. Change in Expanded AISRS - Overall Inattentive (IA) Subscale Score

    9-item subscale of the AISRS assessing inattentive symptoms of ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 27; higher scores indicate greater overall inattentive symptoms.

    Time frame: Baseline, Week 3

  2. Change in Expanded AISRS - Overall Inattentive (IA) Subscale Score

    9-item subscale of the AISRS assessing inattentive symptoms of ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 27; higher scores indicate greater overall inattentive symptoms.

    Time frame: Baseline, Week 10

  3. Change in Expanded AISRS - Hyperactive/Impulsive (HI) Subscale Score

    9-item subscale of the AISRS assessing hyperactive/impulsive symptoms of ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 27; higher scores indicate greater hyperactive/impulsive symptoms.

    Time frame: Baseline, Week 3

  4. Change in Expanded AISRS - Hyperactive/Impulsive (HI) Subscale Score

    9-item subscale of the AISRS assessing hyperactive/impulsive symptoms of ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 27; higher scores indicate greater hyperactive/impulsive symptoms.

    Time frame: Baseline, Week 10

  5. Change from Baseline in Clinical Global Impression-Severity (CGI-S) Scale Score

    1-item clinician-rated assessment of the severity of a subject's mental illness. The severity of illness is rated as follows: 0 (not assessed), 1 (normal, not at all ill), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill), 7 (among the most extremely ill subjects). The total score is the numerical ranking provided by the clinician.

    Time frame: Baseline, Week 3

  6. Change from Baseline in Clinical Global Impression-Severity (CGI-S) Scale Score

    1-item clinician-rated assessment of the severity of a subject's mental illness. The severity of illness is rated as follows: 0 (not assessed), 1 (normal, not at all ill), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill), 7 (among the most extremely ill subjects). The total score is the numerical ranking provided by the clinician.

    Time frame: Baseline, Week 10

  7. 11-Hours Post-Dose Time-Sensitive ADHD Symptom Scale (TASS) Score at Visit 3

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 3 (11-hours Post-Dose)

  8. 11-Hours Post-Dose TASS Score at Visit 4

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 4 (11-hours Post-Dose)

  9. 11-Hours Post-Dose TASS Score at Visit 5

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 5 (11-hours Post-Dose)

  10. 11-Hours Post-Dose TASS Score at Visit 6

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 6 (11-hours Post-Dose)

  11. 11-Hours Post-Dose TASS Score at Visit 7

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 7 (11-hours Post-Dose)

  12. 11-Hours Post-Dose TASS Score at Visit 8

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 8 (11-hours Post-Dose)

  13. 11-Hours Post-Dose TASS Score at Visit 9

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 9 (11-hours Post-Dose)

  14. 11-Hours Post-Dose TASS Score at Visit 10

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 10 (11-hours Post-Dose)

  15. 16-Hours Post-Dose TASS Score at Visit 3

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 3 (16-hours Post-Dose)

  16. 16-Hours Post-Dose TASS Score at Visit 4

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 4 (16-hours Post-Dose)

  17. 16-Hours Post-Dose TASS Score at Visit 5

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 5 (16-hours Post-Dose)

  18. 16-Hours Post-Dose TASS Score at Visit 6

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 6 (16-hours Post-Dose)

  19. 16-Hours Post-Dose TASS Score at Visit 7

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 7 (16-hours Post-Dose)

  20. 16-Hours Post-Dose TASS Score at Visit 8

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 8 (16-hours Post-Dose)

  21. 16-Hours Post-Dose TASS Score at Visit 9

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 9 (16-hours Post-Dose)

  22. 16-Hours Post-Dose TASS Score at Visit 10

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 10 (16-hours Post-Dose)

  23. 21-Hours Post-Dose TASS Score at Visit 3

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 3 (21-hours Post-Dose)

  24. 21-Hours Post-Dose TASS Score at Visit 4

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 4 (21-hours Post-Dose)

  25. 21-Hours Post-Dose TASS Score at Visit 5

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 5 (21-hours Post-Dose)

  26. 21-Hours Post-Dose TASS Score at Visit 6

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 6 (21-hours Post-Dose)

  27. 21-Hours Post-Dose TASS Score at Visit 7

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 7 (21-hours Post-Dose)

  28. 21-Hours Post-Dose TASS Score at Visit 8

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 8 (21-hours Post-Dose)

  29. 21-Hours Post-Dose TASS Score at Visit 9

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 9 (21-hours Post-Dose)

  30. 21-Hours Post-Dose TASS Score at Visit 10

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 10 (21-hours Post-Dose)

  31. 24-Hours Post-Dose TASS Score at Visit 3

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 3 (24-hours Post-Dose)

  32. 24-Hours Post-Dose TASS Score at Visit 4

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 4 (24-hours Post-Dose)

  33. 24-Hours Post-Dose TASS Score at Visit 5

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 5 (24-hours Post-Dose)

  34. 24-Hours Post-Dose TASS Score at Visit 6

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 6 (24-hours Post-Dose)

  35. 24-Hours Post-Dose TASS Score at Visit 7

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 7 (24-hours Post-Dose)

  36. 24-Hours Post-Dose TASS Score at Visit 8

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 8 (24-hours Post-Dose)

  37. 24-Hours Post-Dose TASS Score at Visit 9

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 9 (24-hours Post-Dose)

  38. 24-Hours Post-Dose TASS Score at Visit 10

    18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

    Time frame: Week 10 (24-hours Post-Dose)

  39. 11-Hours Post-Dose Smoothness of Effect Scale (AMSES) Score at Visit 3

    5-item assessment of the smoothness of effect of ADHD medication throughout the day following dosing. Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is the sum of responses and ranges from 0 to 20; higher scores indicate greater smoothness of effect of medication.

    Time frame: Week 3 (11-hours Post-Dose)

  40. 11-Hours Post-Dose Smoothness of Effect Scale (AMSES) Score at Visit 8

    5-item assessment of the smoothness of effect of ADHD medication throughout the day following dosing. Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is the sum of responses and ranges from 0 to 20; higher scores indicate greater smoothness of effect of medication.

    Time frame: Week 8 (11-hours Post-Dose)

  41. 11-Hours Post-Dose Smoothness of Effect Scale (AMSES) Score at Visit 10

    5-item assessment of the smoothness of effect of ADHD medication throughout the day following dosing. Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is the sum of responses and ranges from 0 to 20; higher scores indicate greater smoothness of effect of medication.

    Time frame: Week 10 (11-hours Post-Dose)

  42. 16-Hours Post-Dose Smoothness of Effect Scale (AMSES) Score at Visit 3

    5-item assessment of the smoothness of effect of ADHD medication throughout the day following dosing. Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is the sum of responses and ranges from 0 to 20; higher scores indicate greater smoothness of effect of medication.

    Time frame: Week 3 (16-hours Post-Dose)

  43. 16-Hours Post-Dose Smoothness of Effect Scale (AMSES) Score at Visit 8

    5-item assessment of the smoothness of effect of ADHD medication throughout the day following dosing. Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is the sum of responses and ranges from 0 to 20; higher scores indicate greater smoothness of effect of medication.

    Time frame: Week 8 (16-hours Post-Dose)

  44. 16-Hours Post-Dose Smoothness of Effect Scale (AMSES) Score at Visit 10

    5-item assessment of the smoothness of effect of ADHD medication throughout the day following dosing. Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is the sum of responses and ranges from 0 to 20; higher scores indicate greater smoothness of effect of medication.

    Time frame: Week 10 (16-hours Post-Dose)

  45. 21-Hours Post-Dose Smoothness of Effect Scale (AMSES) Score at Visit 3

    5-item assessment of the smoothness of effect of ADHD medication throughout the day following dosing. Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is the sum of responses and ranges from 0 to 20; higher scores indicate greater smoothness of effect of medication.

    Time frame: Week 3 (21-hours Post-Dose)

  46. 21-Hours Post-Dose Smoothness of Effect Scale (AMSES) Score at Visit 8

    5-item assessment of the smoothness of effect of ADHD medication throughout the day following dosing. Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is the sum of responses and ranges from 0 to 20; higher scores indicate greater smoothness of effect of medication.

    Time frame: Week 8 (21-hours Post-Dose)

  47. 21-Hours Post-Dose Smoothness of Effect Scale (AMSES) Score at Visit 10

    5-item assessment of the smoothness of effect of ADHD medication throughout the day following dosing. Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is the sum of responses and ranges from 0 to 20; higher scores indicate greater smoothness of effect of medication.

    Time frame: Week 10 (21-hours Post-Dose)

  48. 24-Hours Post-Dose Smoothness of Effect Scale (AMSES) Score at Visit 3

    5-item assessment of the smoothness of effect of ADHD medication throughout the day following dosing. Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is the sum of responses and ranges from 0 to 20; higher scores indicate greater smoothness of effect of medication.

    Time frame: Week 3 (24-hours Post-Dose)

  49. 24-Hours Post-Dose Smoothness of Effect Scale (AMSES) Score at Visit 8

    5-item assessment of the smoothness of effect of ADHD medication throughout the day following dosing. Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is the sum of responses and ranges from 0 to 20; higher scores indicate greater smoothness of effect of medication.

    Time frame: Week 8 (24-hours Post-Dose)

  50. 24-Hours Post-Dose Smoothness of Effect Scale (AMSES) Score at Visit 10

    5-item assessment of the smoothness of effect of ADHD medication throughout the day following dosing. Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is the sum of responses and ranges from 0 to 20; higher scores indicate greater smoothness of effect of medication.

    Time frame: Week 10 (24-hours Post-Dose)

  51. Change in Adult ADHD Self Report Scale (ASRS) Symptom Checklist Score

    The ASRS is a 31-item questionnaire assessing frequency of ADHD symptoms over the previous 7 days. Items are rate on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is the sum of responses and ranges from 0 to 124; higher scores indicate greater frequency of ADHD symptoms.

    Time frame: Baseline, Week 3

  52. Change in Adult ADHD Self Report Scale (ASRS) Symptom Checklist Score

    The ASRS is a 31-item questionnaire assessing frequency of ADHD symptoms over the previous 7 days. Items are rate on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is the sum of responses and ranges from 0 to 124; higher scores indicate greater frequency of ADHD symptoms.

    Time frame: Baseline, Week 10

  53. Change in Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Score

    The BRIEF-A is a 75-item self-report questionnaire assessing behavioral issues. Items are rated on a 3-point Likert scale: 0 (never), 1 (sometimes), and 2 (often).

    Time frame: Baseline, Week 3

  54. Change in Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Score

    The BRIEF-A is a 75-item self-report questionnaire assessing behavioral issues. Items are rated on a 3-point Likert scale: 0 (never), 1 (sometimes), and 2 (often).

    Time frame: Baseline, Week 10

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The summary data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: Terry.Leon@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jun 2026, 17 months after the start.

Of 44 non-industry phase 4 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 17 months is below that.

Counting every sponsor, half of 62 studies reached it within 38 months; a quarter within 18 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2024
First posted
Aug 29, 2024
StartActual
Jan 29, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Oct 30, 2026
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06577779
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Aug 29, 2024
Start date
Jan 29, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Apr 29, 2026

Study contacts

Terry Leon, MS, RN
Contact
Terry.Leon@nyulangone.org
646-754-4841
Lenard Adler, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylphenidate

Start the discussion